Skip to main content

Advertisement

SpringerLink
Log in

Non–stimulant medications in the treatment of ADHD

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Background

Stimulants are the first–line medication in the psychopharmacological treatment of attention–deficit hyperactivity disorder (ADHD). However, 10 to 30% of all children and adults with ADHD either do not respond to or do not tolerate treatment with stimulants.

Objective

To describe alternative treatment approaches with various non–stimulant agents, especially atomoxetine.

Method

General review of empirically based literature concerning efficacy and safety of the substances.

Results

A large and still increasing body of data supports the usefulness of atomoxetine, a once daily dosing, and new selective noradrenalin reuptake inhibitor, with few side effects. Atomoxetine has been licensed in the US for use in ADHD across the lifespan, and is currently under consideration in Europe. Other non–stimulant substances, such as tricyclic antidepressants (TCAs) and alpha–2–adrenergic agonists, which are used to treat ADHD, are also reviewed. TCAs have been well studied and shown to be efficacious in the treatment of ADHD, but are limited by side effects. The number of studies documenting the efficacy of alpha–2–adrenergic agonists is still limited. Some experimental studies support a potential role of cholinergic drugs such as acetylcholinesterase inhibitors (tacrine, donepezil) as well as novel nicotinic analogues (ABT–418).

Conclusion

Non–stimulant agents have been shown to be effective in treatment of ADHD. Especially, atomoxetine seems promising and newline drugs are in development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abramowicz M (1990) Sudden death in children treated with a tricyclic antidepressant. The Medical Letter on Drugs and Therapeutics. The Medical Letter 32:37–40

    Google Scholar 

  2. Adler LA, Resnick S, Kunz M, Devinsky O (1995) Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 31:785–788

    CAS  PubMed  Google Scholar 

  3. Akhondzadeh S, Tavakolian R, Davari- Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuro-Psychopharmacol Biol Psychiatry 27:841–845

    CAS  Google Scholar 

  4. Aman MG, Armstrong S, Buican B, Sillick T (2002) Four-year follow-up of children with low intelligence and ADHD: a replication. Res Devel Disabil 23:119–134

    Article  Google Scholar 

  5. Antkowiak R, Rajewski A (1998) Administration of moclobemide++ in children with attention deficit hyperactivity disorder. Psychiatr Pol 32:751–757

    CAS  PubMed  Google Scholar 

  6. Aoki C, Go CG, Venkatesan C, Kurose H (1994) Perikaryal and synaptic localization of alpha 2A-adrenergic receptorlike immunoreactivity. Brain Res 650:181–204

    Article  CAS  PubMed  Google Scholar 

  7. Arnsten AF, Steere JC, Hunt RD (1996) The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53:448–455

    CAS  PubMed  Google Scholar 

  8. Arnsten AFT (2001) Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant Drugs and ADHD. Basic and Clinical Neuroscience. Oxford University Press, New York, NY, pp 185–208

  9. Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A (2003) Association of ADHD and conduct disorder–brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44:356–376

    Article  PubMed  Google Scholar 

  10. Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A (2003) Questioning inhibitory control as the specific deficit of ADHD – evidence from brain electrical activity. Journal of Neural Transmission Online First DOI 10.1007/s00702-003-004-8

  11. Barkley RA (1977) A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137–165

    CAS  PubMed  Google Scholar 

  12. Barkley RA, McMurray MB, Edelbrock CS, Robbins K (1990) Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86:184–192

    CAS  PubMed  Google Scholar 

  13. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M (1991) Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762–767

    CAS  PubMed  Google Scholar 

  14. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, Schumacher E (1995) Bupropion versus methylphenidate in the treatment of attention- deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657

    CAS  PubMed  Google Scholar 

  15. Becker K, Wehmeier PM (2003) Atomoxetin zur Behandlung der Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen (ADHS). Psychoneuro 29:472–476

    Article  Google Scholar 

  16. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42:1219–1227

    Article  CAS  PubMed  Google Scholar 

  17. Biederman J, Baldessarini RJ, Goldblatt A, Lapey KA, Doyle A, Hesslein PS (1993) A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:805–813

    CAS  PubMed  Google Scholar 

  18. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S (1993) A doubleblind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32:199–204

    CAS  PubMed  Google Scholar 

  19. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS (1989) A doubleblind placebo controlled study of desipramine in the treatment of ADD: I Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784

    CAS  PubMed  Google Scholar 

  20. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A (1989) A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 28:903–911

    CAS  PubMed  Google Scholar 

  21. Biederman J, Gastfriend DR, Jellinek MS (1986) Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 6:359–363

    CAS  PubMed  Google Scholar 

  22. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ (2002) Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/ hyperactivity disorder. Pediatrics 110:e75

    Article  PubMed  Google Scholar 

  23. Biederman J, Newcorn J, Sprich S (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564–577

    CAS  PubMed  Google Scholar 

  24. Biederman J, Spencer T (1999) Attention- deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234–1242

    Article  CAS  PubMed  Google Scholar 

  25. Biederman J, Spencer T (2000) Nonstimulant treatments for ADHD. Eur Child Adolesc Psychiatry 9 (Suppl 1):I51–I59

    PubMed  Google Scholar 

  26. Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995) Estimation of the association between desipramine and the risk for sudden death in 5- to 14-yearold children. J Clin Psychiatry 56:87–93

    CAS  PubMed  Google Scholar 

  27. Brandeis D, Banaschewski T, Baving L, Georgiewa P, Blanz B, Warnke A, Steinhausen HC, Rothenberger A, Scheuerpflug P (2002) Multicenter P300 brain mapping of impaired attention to cues in hyperkinetic children. J Am Acad Child Adolesc Psychiatry 41:990–998

    PubMed  Google Scholar 

  28. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711

    Article  CAS  PubMed  Google Scholar 

  29. Byrd BF 3rd, Collins HW, Primm RK (1988) Risk factors for severe bradycardia during oral clonidine therapy for hypertension. Arch Intern Med 148:729–733

    Article  PubMed  Google Scholar 

  30. Cantwell DP, Swanson J, Connor DF (1997) Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 36:539–544

    Article  CAS  PubMed  Google Scholar 

  31. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochemistry 55:1067–1070

    CAS  Google Scholar 

  32. Carrey N, MacMaster FP, Sparkes SJ, Khan SC, Kusumakar V (2002) Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series. J Child Adolesc Psychopharmacol 12:331–336

    PubMed  Google Scholar 

  33. Casat CD, Pleasants DZ, Schroeder DH, Parler DW (1989) Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25:198–201

    CAS  PubMed  Google Scholar 

  34. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL (1997) Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36:589–596

    CAS  PubMed  Google Scholar 

  35. Castellanos FX, Tannock R (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nature reviews. Neuroscience 3:617–628

    CAS  PubMed  Google Scholar 

  36. Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y (2003) Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 73:178–191

    CAS  PubMed  Google Scholar 

  37. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ (1995) Guanfacine treatment of comorbid attentiondeficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140–1146

    CAS  PubMed  Google Scholar 

  38. Chouinard G, Annable L, Bradwejn J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) 83:126–128

    CAS  PubMed  Google Scholar 

  39. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J (1996) Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321

    CAS  PubMed  Google Scholar 

  40. Connor DF, Barkley RA, Davis HT (2000) A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 39:15–25

    CAS  Google Scholar 

  41. Connor DF, Fletcher KE, Swanson JM (1999) A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:1551–1559

    CAS  PubMed  Google Scholar 

  42. Cookson J (1993) Side-effects of antidepressants. Br J Psychiatry (Suppl):20–24

    Google Scholar 

  43. Coulter CL, Happe HK, Bergman DA, Murrin LC (1995) Localization and quantification of the dopamine transporter: comparison of [3H]WIN 35.428 and [125I]RTI-55. Brain Res 690:217–224

    Article  CAS  PubMed  Google Scholar 

  44. Cox WH Jr (1982) An indication for use of imipramine in attention deficit disorder. Am J Psychiatry 139:1059–1060

    PubMed  Google Scholar 

  45. Dalack GW, Healy DJ, Meador- Woodruff JH (1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155:1490–1501

    CAS  PubMed  Google Scholar 

  46. Daly JM, Wilens T (1998) The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am 45:1123–1135

    CAS  PubMed  Google Scholar 

  47. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L (2001) Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307–314

    Article  CAS  PubMed  Google Scholar 

  48. DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M (2002) GW320659 for the treatment of attention- deficit/hyperactivity disorder in children. J Am Acad Child Adolesc Psychiatry 41:914–920

    Article  PubMed  Google Scholar 

  49. Diamond IR, Tannock R, Schachar RJ (1999) Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 38:402–409

    Article  CAS  PubMed  Google Scholar 

  50. Dillon DC, Salzman IJ, Schulsinger DA (1985) The use of imipramine in Tourette’s syndrome and attention deficit disorder: case report. J Clin Psychiatry 46:348–349

    CAS  PubMed  Google Scholar 

  51. Downey KK, Stelson FW, Pomerleau OF, Giordani B (1997) Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. J Nerv Ment Dis 185:32–38

    Article  CAS  PubMed  Google Scholar 

  52. DuPaul GJ, Barkley RA, Connor DF (1998) Stimulant medications for ADHD children. In: Barkley RA (ed) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guildford, New York, pp 510–551

  53. DuPaul GJ, Barkley RA, McMurray MB (1994) Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry 33: 894–903

    CAS  PubMed  Google Scholar 

  54. Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 36:141–155

    Article  CAS  PubMed  Google Scholar 

  55. Eli-Lilly&Co (2003) StratteraTM (atomoxetine HCl). Internet: http://pi.lilly. com/us/strattera-pi.pdf

  56. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD (1992) A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53:77–82

    CAS  PubMed  Google Scholar 

  57. Faraone SV, Biederman J (2002) Pathophysiology of Attention Deficit Hyperactivity Disorder. In: Davis K, Charney D, Coyle JT, Nemeroff C (eds) ACNP’s Fifth Generation of Progress. Lipponcott, Williams, and Wilkens, New York, pp 577–596

  58. Faraone SV, Wilens T (2003) Does stimulant treatment lead to substance use disorders? J Clin Psychiatry 64 (Suppl 11):9–13

    CAS  Google Scholar 

  59. Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, Chapieski L, Trinidad K, Como P, Jankovic J (1996) A controlled trial of deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder. Neurology 46:965–968

    CAS  PubMed  Google Scholar 

  60. Fenichel RF (1995) Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol 5:155–156

    Google Scholar 

  61. Findling RL (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 6:165–175

    CAS  PubMed  Google Scholar 

  62. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S (1999) Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 56:330–336

    PubMed  Google Scholar 

  63. Gammon GD, Brown TF (1993) Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1–10

    Google Scholar 

  64. Garfinkel BD, Wender PH, Sloman L, O’Neill I (1983) Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 22:343–348

    CAS  PubMed  Google Scholar 

  65. Gehlert DR, Gackenheimer SL, Robertson DW (1993) Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neuroscience Letters 157:203–206

    CAS  PubMed  Google Scholar 

  66. Gittelman R (1980) Childhood disorders. In: Klein D, Quitkin F, Rifkin A, Gittelman R (eds) Drug Treatment of Adult and Childhood Disorders. Williams and Wilkins, Baltimore, pp 576–756

  67. Gittelman-Klein R (1974) Pilot clinical trial of impramine in hyperkinetic children. In: Conners C (ed) Clinical Use of Stimulant Drugs in Children. Excerpta Medica, The Hague, the Netherlands, pp 192–201

  68. Green WH (1992) Nonstimulant drugs in the treatment of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 1:449–465

    Google Scholar 

  69. Greenberg L,Yellin A, Spring C, Metcalf M (1975) Clinical effects of impramine and methylphenidate in hyperactive children. Int J Ment Health 4:144–156

    Google Scholar 

  70. Greenhill L (1995) Attention-deficit/hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am 4:123–168

    Google Scholar 

  71. Gross MD (1973) Imipramine in the treatment of minimal brain dysfunction in children. Psychosomatics 14:283–285

    CAS  PubMed  Google Scholar 

  72. Gualtieri CT, Evans RW (1988) Motor performance in hyperactive children treated with imipramine. Percept Mot Skills 66:763–769

    CAS  PubMed  Google Scholar 

  73. Guengerich FP, Bell LC, Okazaki O (1995) Interpretations of cytochrome P450 mechanisms from kinetic studies. Biochemie 77:573–580

    Article  CAS  Google Scholar 

  74. Hazell PL, Stuart JE (2003) A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886–894

    PubMed  Google Scholar 

  75. Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH (1995) An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 31:779–783

    CAS  PubMed  Google Scholar 

  76. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149–156

    Article  CAS  PubMed  Google Scholar 

  77. Heiligenstein JH, Spencer TJ, Faries DE, Biederman J, Kratochvil C, Conners CF (2000) Efficacy of atomexetine vs. placebo in pediatric outpatients with ADHD (Poster). In: 47th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. New York, NY

  78. Hoge SK, Biederman J (1986) A case of Tourette’s syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 47:478–479

    CAS  PubMed  Google Scholar 

  79. Hornig-Rohan M, Amsterdam JD (2002) Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Progr Neuropsychopharmacol Biol Psychiatry 26: 585–589

    CAS  Google Scholar 

  80. Horrigan JP, Barnhill LJ (1995) Guanfacine for the treatment of attentiondeficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5:215–223

    Google Scholar 

  81. Huessy HR, Wright AL (1970) The use of imipramine in children’s behavior disorders. Acta Paedopsychiatry 37:194–199

    CAS  Google Scholar 

  82. Hunt RD (1989) Advances in pediatric psychopharmacology. In: Annual Meetings of the American Academy of Child and Adolescent Psychiatry. New York

  83. Hunt RD, Arnsten AF, Asbell MD (1995) An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50–54

    Article  CAS  PubMed  Google Scholar 

  84. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R (1999) Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ): i–viii, 1–341

    Google Scholar 

  85. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R (1998) The treatment of attention-deficit/hyperactivity disorder: a evidence report.Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, MD

  86. Jankovic J (1993) Deprenyl in attention deficit associated with Tourette’s syndrome. Arch Neurol 50:286–288

    CAS  PubMed  Google Scholar 

  87. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology (Berl) 108:485–494

    CAS  PubMed  Google Scholar 

  88. Kelsey D, Sumner C, Sutton V, Malcom S, Schuh KJ, Allen AJ (2003) Once-daily Atomoxetine in Childhood ADHD: Continuous Symptom Relief. In: ESCAP. Lilly, Paris

  89. Kibler LE, Gazes PC (1977) Effect of clonidine on atrioventricular conduction. J Am Med Assoc 238:1930–1932

    Article  CAS  Google Scholar 

  90. Kimber J, Sivenandan M, Watson L, Mathias CJ (2001) Age- and gender-related growth hormone responses to intravenous clonidine in healthy adults. Growth Horm IGF Res 11:128–135

    Article  CAS  PubMed  Google Scholar 

  91. Kollins SH (2003) Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 64 (Suppl 11):14–18

    CAS  Google Scholar 

  92. Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, Burke WJ (2001) An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:167–170

    Article  CAS  PubMed  Google Scholar 

  93. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776–784

    PubMed  Google Scholar 

  94. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attentiondeficit/ hyperactivity disorder. Expert Opin Pharmacother 4:1165–1174

    CAS  PubMed  Google Scholar 

  95. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K,Ackenheil M (2002) Stimulant- like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5:111–113

    Article  CAS  PubMed  Google Scholar 

  96. Krausz M (2002) Efficacy review of antipsychotics. Curr Med Res Opin 18 Suppl 3:s8–s12

    Article  PubMed  Google Scholar 

  97. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, Holman TL, Moser DJ, Paulsen JS (2001) Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 13:129–134

    Article  CAS  PubMed  Google Scholar 

  98. Kupietz SS, Balka EB (1976) Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology (Berl) 50:29–33

    CAS  PubMed  Google Scholar 

  99. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ (1991) Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 48:324–328

    CAS  PubMed  Google Scholar 

  100. Leonard HL, Meyer MC, Swedo SE, Richter D, Hamburger SD, Allen AJ, Rapoport JL, Tucker E (1995) Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 34:1460–1468

    CAS  PubMed  Google Scholar 

  101. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J (1996) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 123:55–63

    CAS  PubMed  Google Scholar 

  102. Lord, Paisley (2000) The Clinical Effectiveness and Cost-Effectiveness of Methylphenidate for Hyperactivity in Childhood. National Institute for Clinical Excellence, London

  103. Luh J, Pliszka SR, Olvers R, Tatum R (1996) An open trial of venlafaxine in the treatment of attention hyperactivity disorder.New Clinical Drug Evaluation Unit Program, Orlando, Fla

  104. Maidment ID (2003) The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol 17:332–336

    Article  CAS  PubMed  Google Scholar 

  105. Malhotra S, Santosh PJ (1998) An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 37:364–371

    CAS  PubMed  Google Scholar 

  106. Mannuzza S, Klein RG (2000) Longterm prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 9:711–726

    CAS  Google Scholar 

  107. McCracken JT, Sallee FR, Leonard HL, Dunn DW, Budman CL, Geller DA, Milton DR, Layton LL, Feldman PD, Spencer T, Allen AJ (2003) Improvement of ADDHD by Atomoxetine in Children with Tic Disorders (Poster). In: AACAP. Miami

  108. Mefford IN, Potter WZ (1989) A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Medical Hypotheses 29:33–42

    CAS  PubMed  Google Scholar 

  109. Mereu G, Yoon KW, Boi V, Gessa GL, Naes L, Westfall TC (1987) Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141:395–399

    Article  CAS  PubMed  Google Scholar 

  110. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D,Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120

    Article  CAS  PubMed  Google Scholar 

  111. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K,West S, Kelsey D,Wernicke J,Trapp NJ,Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901

    Article  PubMed  Google Scholar 

  112. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83

    PubMed  Google Scholar 

  113. Miller A (1999) Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives. Can J Psychiatry 44:1017–1024

    CAS  PubMed  Google Scholar 

  114. Motavalli Mukaddes N, Abali O (2004) Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 58:92–95

    Article  PubMed  Google Scholar 

  115. MTA-Cooperative-Group (1999) A 14- month randomized clinical trial of treatment strategies for attentiondeficit/ hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073–1086

    Article  PubMed  Google Scholar 

  116. Network SIG (2001) Attention Deficit and Hyperkinetic Disorders in Children and Young People. Scotish Intercollegiate Guidelines Network (SIGN), Edinburgh

  117. Newcorn J, Michelson D, Spencer T, et al. (2003) Atomoxetine treatment in children/adolescent ADHD with comorbid ODD (Poster). In: 49th ESCAP. Paris

  118. Olvera RL, Pliszka SR, Luh J, Tatum R (1996) An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6:241–250

    CAS  PubMed  Google Scholar 

  119. Perwien AR, Faries D, Kratochvil C (2003) Long-Term Effects of Atomoxetine on Health-Related Quality of Life (Poster). In: AACAP. Lilly, Miami

  120. Pliszka SR (2001) Comparing the effects of stimulant and non-stimulant agents on catecholamine function: implications for theories of ADHD. In: Solanto MV,Arnsten AFT, Castellanos FX (eds) Stimulant Drugs and ADHS: Basic and Clinical Neuroscience. Oxford University Press, New York, NY, pp 332–352

  121. Pliszka SR (1989) Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 28:882–887

    CAS  PubMed  Google Scholar 

  122. Pliszka SR (2003) Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectrums 8:253–258

    PubMed  Google Scholar 

  123. Pliszka SR, McCracken JT, Maas JW (1996) Catecholamines in attentiondeficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264–272

    CAS  PubMed  Google Scholar 

  124. Popper CW (1997) Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 58 (Suppl 14):14–29; discussion 30–11

    CAS  Google Scholar 

  125. Popper CW (2000) Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 9:605–646, viii

    CAS  Google Scholar 

  126. Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA, Bostic JQ (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204

    Article  CAS  PubMed  Google Scholar 

  127. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR (1996) Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 35:599–605

    Article  CAS  PubMed  Google Scholar 

  128. Rapoport J (1965) Childhood behavior and learning problems treated with imipramine. Int J Neuropsychiatry 1:635–642

    CAS  PubMed  Google Scholar 

  129. Rapoport JL, Quinn PO, Bradbard G, Riddle KD, Brooks E (1974) Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Arch Gen Psychiatry 30:789–793

    CAS  PubMed  Google Scholar 

  130. Rapport MD, Carlson GA, Kelly KL, Pataki C (1993) Methylphenidate and desipramine in hospitalized children: I Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32:333–342

    CAS  PubMed  Google Scholar 

  131. Riddle MA, Hardin MT, Cho SC, Woolston JL, Leckman JF (1988) Desipramine treatment of boys with attention- deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 27:811–814

    CAS  PubMed  Google Scholar 

  132. Riddle MA, Nelson JC, Kleinman CS, Rasmusson A, Leckman JF, King RA, Cohen DJ (1991) Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104–108

    CAS  PubMed  Google Scholar 

  133. Riggs PD, Leon SL, Mikulich SK, Pottle LC (1998) An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 37:1271–1278

    Article  CAS  PubMed  Google Scholar 

  134. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA (2002) Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metabolism and Disposition: Biol Fate Chem 30:319–323

    CAS  Google Scholar 

  135. Rugino TA, Samsock TC (2003) Modafinil in children with attentiondeficit hyperactivity disorder. Pediatr Neurol 29:136–142

    PubMed  Google Scholar 

  136. Sagvolden T, Sergeant JA (1998) Attention deficit/hyperactivity disorder – from brain dysfunctions to behaviour. Behav Brain Res 94:1–10

    PubMed  Google Scholar 

  137. Santosh PJ, Taylor E (2004) Atomoxetine and other non-stimulant treatments of ADHD – Commentary. (Submitted)

  138. Santosh PJ, Taylor E (2000) Stimulant drugs. Eur Child Adolesc Psychiatry 9 (Suppl 1):I27–I43

    Article  PubMed  Google Scholar 

  139. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA (2003) Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metabolism and Disposition: Biol Fate Chem 31:98–107

    CAS  Google Scholar 

  140. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067–1074

    Article  CAS  PubMed  Google Scholar 

  141. Schachter HM, Pham B, King J, Langford S, Moher D (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475–1488

    CAS  PubMed  Google Scholar 

  142. Shytle RD, Silver AA, Wilkinson BJ, Sanberg PR (2002) A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder. World J Biol Psychiatry 3:150–155

    PubMed  Google Scholar 

  143. Silva RR, Munoz DM, Alpert M (1996) Carbamazepine use in children and adolescents with features of attentiondeficit hyperactivity disorder: a metaanalysis. J Am Acad Child Adolesc Psychiatry 35:352–358

    Article  CAS  PubMed  Google Scholar 

  144. Silver LB (1999) Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr Clin North Am 46:965–975

    CAS  PubMed  Google Scholar 

  145. Simeon JG, Ferguson HB, Van Wyck Fleet J (1986) Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 31:581–585

    CAS  PubMed  Google Scholar 

  146. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB (1995) The treatment of attentiondeficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95:74–81

    CAS  PubMed  Google Scholar 

  147. Snyder R, Turgay A, Aman M, Binder C, Fisman S,Carroll A (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026–1036

    PubMed  Google Scholar 

  148. Solanto MV, Arnsten AFT, Castellanos FX (2001) The Neuroscience of Stimulant Drug Action in ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant Drugs and ADHS: Basic and Clinical Neuroscience. Oxford University Press, New York, NY, pp 355–379

  149. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV (2002) A doubleblind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649–656

    Article  CAS  PubMed  Google Scholar 

  150. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251–265

    CAS  PubMed  Google Scholar 

  151. Spencer T, Biederman J, Steingard R, Wilens T (1993) Bupropion exacerbates tics in children with attentiondeficit hyperactivity disorder and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 32:211–214

    CAS  PubMed  Google Scholar 

  152. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S (1996) Pharmacotherapy of attentiondeficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432

    CAS  PubMed  Google Scholar 

  153. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695

    CAS  PubMed  Google Scholar 

  154. Spencer T, Biederman J, Wilens T, Steingard R, Geist D (1993) Nortriptyline treatment of children with attention- deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 32:205–210

    CAS  PubMed  Google Scholar 

  155. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept,placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147

    CAS  PubMed  Google Scholar 

  156. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention- deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443

    CAS  PubMed  Google Scholar 

  157. Sullivan MA, Covey LS (2002) Nicotine dependence: the role for antidepressants and anxiolytics. Curr Opin Investig Drugs 3:262–271

    CAS  PubMed  Google Scholar 

  158. Swanson J (2003) Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17:117–131

    PubMed  Google Scholar 

  159. Swanson J (1993) Effect of Stimulant medication on hyperactive children.A Review of Reviews. Except. Child 60:154–162

    Google Scholar 

  160. Swanson J, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L (1995) Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301–304

    Google Scholar 

  161. Swanson J, Kinsbourne M, Roberts W, Zucker K (1978) Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 61:21–29

    CAS  PubMed  Google Scholar 

  162. Swanson JM (2003) Role of executive function in ADHD. J Clin Psychiatry 64 (Suppl 14):35–39

    CAS  Google Scholar 

  163. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP (1998) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351:429–433

    Article  CAS  PubMed  Google Scholar 

  164. Taylor E, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Döpfner M, Rothenberger A, Santosh P, Sergeant J, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) Clinical Guidelines for Hyperkinetic Disorder. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–I30

    Google Scholar 

  165. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M (1987) Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 17:121–143

    CAS  PubMed  Google Scholar 

  166. Taylor FB, Russo J (2001) Comparing guanfacine and dextroamphetamine for the treatment of adult attentiondeficit/ hyperactivity disorder. J Clin Psychopharmacol 21:223–228

    CAS  PubMed  Google Scholar 

  167. Taylor FB, Russo J (2000) Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10:311–320

    CAS  PubMed  Google Scholar 

  168. Thapar A, Fowler T, Rice F, Scourfield J, van den Bree M, Thomas H, Harold G, Hay D (2003) Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry 160:1985–1989

    Article  PubMed  Google Scholar 

  169. Tourette-Syndrome-Study-Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial.Neurology 58:527–536

    PubMed  Google Scholar 

  170. Trott GE, Friese HJ, Menzel M, Nissen G (1992) Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology (Berl) 106 (Suppl):S134–136

    PubMed  Google Scholar 

  171. Varley CK, Vincent J, Varley P, Calderon R (2001) Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Comprehen Psychiatry 42:228–233

    Article  CAS  Google Scholar 

  172. Voelker S, Lachar D, Gdowski CL (1983) The Personality Inventory for Children and response to methylphenidate: preliminary evidence for predictive utility. J Pediatr Psychol 8:161–169

    CAS  PubMed  Google Scholar 

  173. Walsh BT, Giardina EG, Sloan RP, Greenhill L, Goldfein J (1994) Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry 33:191–197

    CAS  PubMed  Google Scholar 

  174. Watter N, Dreifuss FE (1973) Modification of hyperkinetic behavior by nortriptyline. Va Med Mon (1918) 100:123–126

    CAS  PubMed  Google Scholar 

  175. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen AJ (2003) Placebo-controlled Study of Once-daily Atomoxetine in the School Setting. In: ESCAP. Lilly, Paris

  176. Wender PH, Reimherr FW (1990) Bupropion treatment of attentiondeficit hyperactivity disorder in adults. Am J Psychiatry 147:1018–1020

    CAS  PubMed  Google Scholar 

  177. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D (2004) Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 24:30–35

    PubMed  Google Scholar 

  178. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26:729–740

    CAS  PubMed  Google Scholar 

  179. Wernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63 (Suppl 12):50–55

    CAS  PubMed  Google Scholar 

  180. Werry JS, Aman MG, Diamond E (1980) Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 21:27–35

    CAS  PubMed  Google Scholar 

  181. Westfall TC, Grant H, Perry H (1983) Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 14:321–325

    Article  CAS  PubMed  Google Scholar 

  182. Wilens TE, Biederman J, Abrantes AM, Spencer TJ (1996) A naturalistic assessment of protriptyline for attention- deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 35:1485–1490

    CAS  PubMed  Google Scholar 

  183. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A (1996) Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35:1491–1501

    CAS  PubMed  Google Scholar 

  184. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T (1993) Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343–349

    CAS  PubMed  Google Scholar 

  185. Wilens TE, Biederman J, Mick E, Spencer TJ (1995) A systematic assessment of tricyclic antidepressants in the treatment of adult attentiondeficit hyperactivity disorder. J Nerv Ment Dis 183:48–50

    CAS  PubMed  Google Scholar 

  186. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D (1996) Six-week, doubleblind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 153:1147–1153

    CAS  PubMed  Google Scholar 

  187. Wilens TE, Biederman J, Spencer T (1994) Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 33:424–426

    CAS  PubMed  Google Scholar 

  188. Wilens TE, Biederman J, Spencer TJ (1998) Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs 9:347–356

    CAS  Google Scholar 

  189. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931–1937

    CAS  PubMed  Google Scholar 

  190. Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB (2000) Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol 10:217–222

    Article  CAS  PubMed  Google Scholar 

  191. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185

    PubMed  Google Scholar 

  192. Wilens TE, Spencer TJ (2000) The stimulants revisited. Child Adolesc Psychiatr Clin North Am 9:573–603, viii

    CAS  Google Scholar 

  193. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, Parekh A (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282–288

    Article  CAS  PubMed  Google Scholar 

  194. Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D (1999) Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 38:614–619; discussion 619–622

    CAS  PubMed  Google Scholar 

  195. Winsberg BG, Bialer I, Kupietz S, Tobias J (1972) Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. Am J Psychiatry 128:1425–1431

    CAS  PubMed  Google Scholar 

  196. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J (2003) Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13:53–63

    Article  PubMed  Google Scholar 

  197. Wong DT, Bymaster FP, Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sciences 57:411–44

    Article  CAS  PubMed  Google Scholar 

  198. Yamamoto BK, Novotney S (1998) Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochemistry 71:274–280

    CAS  Google Scholar 

  199. Yepes LE, Balka EB, Winsberg BG, Bialer I (1977) Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry 18:39–52

    CAS  PubMed  Google Scholar 

  200. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42:962–966

    CAS  PubMed  Google Scholar 

  201. Zametkin AJ, Rapoport JL (1987) Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review. In: Meltzer HY (ed) Psychopharmacology: The third Generation of Progress. Raven Press, New York, pp 837–847

Download references

Author information

Authors and Affiliations

  1. Child and Adolescent Psychiatry, University of Göttingen, von-Siebold-Str. 5, 37075, Göttingen, Germany

    T. Banaschewski, V. Roessner & A. Rothenberger

  2. Lilly Deutschland GmbH, Bad Homburg, Germany

    R. W. Dittmann

  3. Psychosomatic Department, Children’s Hospital, University of Hamburg, Hamburg, Germany

    R. W. Dittmann

  4. Dept. of Psychological Medicine, Hospital for Children, Great Ormond Street, London, UK

    P. Janardhanan Santosh

Authors
  1. T. Banaschewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Roessner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. W. Dittmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Janardhanan Santosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Rothenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Banaschewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Banaschewski, T., Roessner, V., Dittmann, R.W. et al. Non–stimulant medications in the treatment of ADHD . European Child & Adolescent Psychiatry 13 (Suppl 1), i102–i116 (2004). https://doi.org/10.1007/s00787-004-1010-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-004-1010-x

Keywords

Search

Navigation